The renaissance of polypharmacology in the development of anti-cancer therapeutics: Inhibition of the "Triad of Death" in cancer by Di-2-pyridylketone thiosemicarbazones.

@article{Jansson2015TheRO,
  title={The renaissance of polypharmacology in the development of anti-cancer therapeutics: Inhibition of the "Triad of Death" in cancer by Di-2-pyridylketone thiosemicarbazones.},
  author={Patric J. Jansson and Danuta S. Kalinowski and Darius J. R. Lane and Žaklina Kova{\vc}evi{\'c} and Nicole A Seebacher and Leyla Fouani and Sumit Sahni and Angelica M. Merlot and Des. R. Richardson},
  journal={Pharmacological research},
  year={2015},
  volume={100},
  pages={255-60}
}
Cancer is a disease that is a "moving target", since as the condition progresses, the molecular targets change and evolve. Moreover, due to clonal selection, a specific anti-cancer drug with one molecular target may only be effective for a limited time period before drug resistance results and the agent becomes ineffective. Hence, the concept of an anti… CONTINUE READING